Jose M Teixeira

List of Publications by Year in descending order

76 papers	3,952 citations	109321 35 h-index	118850 62 g-index
78 all docs	78 docs citations	78 times ranked	5529 citing authors

#	Article	IF	Citations
1	Obesity-induced follicular phase endometrial proteome dysregulation in a well-phenotyped population. F&S Science, 2022, , .	0.9	0
2	Summary of the proceedings of the Basic Science of Uterine Fibroids meeting: new developments (February 28, 2020). F&S Science, 2021, 2, 88-100.	0.9	5
3	Transcriptome Analyses of Myometrium from Fibroid Patients Reveals Phenotypic Differences Compared to Non-Diseased Myometrium. International Journal of Molecular Sciences, 2021, 22, 3618.	4.1	13
4	Putative human myometrial and fibroid stem-like cells have mesenchymal stem cell and endometrial stromal cell properties. Human Reproduction, 2020, 35, 44-57.	0.9	18
5	ARID1A Mutations Promote P300-Dependent Endometrial Invasion through Super-Enhancer Hyperacetylation. Cell Reports, 2020, 33, 108366.	6.4	36
6	InÂVivo Cell Fate Tracing Provides No Evidence for Mesenchymal to Epithelial Transition in Adult Fallopian Tube and Uterus. Cell Reports, 2020, 31, 107631.	6.4	29
7	ARID1A and PI3-kinase pathway mutations in the endometrium drive epithelial transdifferentiation and collective invasion. Nature Communications, 2019, 10, 3554.	12.8	96
8	Integrated Epigenome, Exome, and Transcriptome Analyses Reveal Molecular Subtypes and Homeotic Transformation in Uterine Fibroids. Cell Reports, 2019, 29, 4069-4085.e6.	6.4	49
9	GnRH Transactivates Human AMH Receptor Gene via Egr1 and FOXO1 in Gonadotrope Cells. Neuroendocrinology, 2019, 108, 65-83.	2.5	15
10	Developmental Genetics of the Female Reproductive Tract. , 2019, , 129-153.		3
11	Label-Retaining, Putative Mesenchymal Stem Cells Contribute to Murine Myometrial Repair During Uterine Involution. Stem Cells and Development, 2018, 27, 1715-1728.	2.1	12
12	Nuclear PTEN Localization Contributes to DNA Damage Response in Endometrial Adenocarcinoma and Could Have a Diagnostic Benefit for Therapeutic Management of the Disease. Molecular Cancer Therapeutics, 2018, 17, 1995-2003.	4.1	12
13	Gain-of-function Î²-catenin in the uterine mesenchyme leads to impaired implantation and decidualization. Journal of Endocrinology, 2017, 233, 119-130.	2.6	21
14	Pathogenic Anti-MÃ¼llerian Hormone Variants in Polycystic Ovary Syndrome. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 2862-2872.	3.6	80
15	Specific deletion of LKB1/ Stk11 in the MÃ¼llerian duct mesenchyme drives hyperplasia of the periurethral stroma and tumorigenesis in male mice. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 3445-3450.	7.1	4
16	Histone chaperone APLF regulates induction of pluripotency in murine fibroblasts. Development (Cambridge), 2017, 144, e1.2-e1.2.	2.5	0
17	Germ cell specific overactivation of WNT/Î²catenin signalling has no effect on folliculogenesis but causes fertility defects due to abnormal foetal development. Scientific Reports, 2016, 6, 27273.	3.3	29
18	Histone chaperone APLF regulates induction of pluripotency in murine fibroblasts. Journal of Cell Science, 2016, 129, 4576-4591.	2.0	12

#	Article	IF	Citations
19	Epidemiological and genetic clues for molecular mechanisms involved in uterine leiomyoma development and growth. Human Reproduction Update, 2015, 21, 593-615.	10.8	143
20	Hyperplasia and fibrosis in mice with conditional loss of the TSC2 tumor suppressor in MÃ¼llerian duct mesenchyme-derived myometria. Molecular Human Reproduction, 2014, 20, 1126-1134.	2.8	6
21	Loss of LKB1 and PTEN tumor suppressor genes in the ovarian surface epithelium induces papillary serous ovarian cancer. Carcinogenesis, 2014, 35, 546-553.	2.8	64
22	Induction of WNT inhibitory factor 1 expression by MÃ¼llerian inhibiting substance/antiMullerian hormone in the MÃ¼llerian duct mesenchyme is linked to MÃ¼llerian duct regression. Developmental Biology, 2014, 386, 227-236.	2.0	16
23	Mesenchymal-to-Epithelial Transition Contributes to Endometrial Regeneration Following Natural and Artificial Decidualization. Stem Cells and Development, 2013, 22, 964-974.	2.1	90
24	PTEN loss and HOXA10 expression are associated with ovarian endometrioid adenocarcinoma differentiation and progression. Carcinogenesis, 2013, 34, 893-901.	2.8	33
25	Stromal Liver Kinase B1 [STK11] Signaling Loss Induces Oviductal Adenomas and Endometrial Cancer by Activating Mammalian Target of Rapamycin Complex 1. PLoS Genetics, 2012, 8, e1002906.	3.5	44
26	The MÃ¼llerian inhibiting substance type 2 receptor suppresses tumorigenesis in testes with sustained Î²-catenin signaling. Carcinogenesis, 2012, 33, 2351-2361.	2.8	15
27	Deletion of Tuberous Sclerosis 1 in Somatic Cells of the Murine Reproductive Tract Causes Female Infertility. Endocrinology, 2012, 153, 404-416.	2.8	41
28	Human ovarian cancer stem/progenitor cells are stimulated by doxorubicin but inhibited by Mullerian inhibiting substance. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2358-2363.	7.1	112
29	Altered LKB1/AMPK/TSC1/TSC2/mTOR signaling causes disruption of Sertoli cell polarity and spermatogenesis. Human Molecular Genetics, 2012, 21, 4394-4405.	2.9	73
30	Endometrial stromal beta-catenin is required for steroid-dependent mesenchymal-epithelial cross talk and decidualization. Reproductive Biology and Endocrinology, 2012, 10, 75.	3.3	42
31	149. Contribution of the Endometrial Microenvironment to Carcinogenesis.. Biology of Reproduction, 2012, 87, 149-149.	2.7	1
32	In vitro maturation (IVM) of murine and human germinal vesicle (GV)â€“stage oocytes by coculture with immortalized human fallopian tube epithelial cells. Fertility and Sterility, 2011, 95, 1344-1348.	1.0	9
33	Mammalian Target of Rapamycin Is a Therapeutic Target for Murine Ovarian Endometrioid Adenocarcinomas with Dysregulated Wnt/Î²-Catenin and PTEN. PLoS ONE, 2011, 6, e20715.	2.5	46
34	Stromal Deletion of the APC Tumor Suppressor in Mice Triggers Development of Endometrial Cancer. Cancer Research, 2011, 71, 1584-1596.	0.9	53
35	Adenomatous Polyposis Coli (APC) Is Essential for Maintaining the Integrity of the Seminiferous Epithelium. Molecular Endocrinology, 2011, 25, 1725-1739.	3.7	35
36	Human Endometrial Cells Express Elevated Levels of Pluripotent Factors and Are More Amenable to Reprogramming into Induced Pluripotent Stem Cells. Endocrinology, 2011, 152, 1080-1089.	2.8	37

#	Article	IF	Citations
37	The Rate of In Vitro Maturation of Primary Follicles From Adult Mice and the Quality of Oocytes is Improved in the Absence of Anti-MÃ¼llerian Hormone. Reproductive Sciences, 2011, 18, 334-341.	2.5	9
38	APC (Adenomatous Polyposis Coli), a Tumor Suppressor Gene, Is Required for Maintenance of Sertoli Cell Polarity and Microtubules Integrity.. Biology of Reproduction, 2011, 85, 44-44.	2.7	0
39	Constitutive WNT/Beta-Catenin Signaling in Murine Sertoli Cells Disrupts Their Differentiation and Ability to Support Spermatogenesis1. Biology of Reproduction, 2010, 82, 422-432.	2.7	121
40	Uterine Leiomyomas Exhibit Fewer Stem/Progenitor Cell Characteristics When Compared With Corresponding Normal Myometrium. Reproductive Sciences, 2010, 17, 158-167.	2.5	67
41	Focal MÃ¼llerian duct retention in male mice with constitutively activated Î²-catenin expression in the MÃ¼llerian duct mesenchyme. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 16142-16147.	7.1	30
42	MÃ¼llerian inhibiting substance preferentially inhibits stem/progenitors in human ovarian cancer cell lines compared with chemotherapeutics. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 18874-18879.	7.1	92
43	Development of an efficiently cleaved, bioactive, highly pure FLAG-tagged recombinant human Mullerian Inhibiting Substance. Protein Expression and Purification, 2010, 70, 32-38.	1.3	15
44	Mullerian Mesenchyme-Specific Activation of Wnt/Beta-Catenin Signaling Inhibits Mullerian Duct Regression and Contributes to Male Infertility.. Biology of Reproduction, 2010, 83, 91-91.	2.7	1
45	A Potential Role for Mesenchymal-to-Epithelial Transition During Endometrial Regeneration.. Biology of Reproduction, 2010, 83, 156-156.	2.7	0
46	Parthenogenesis in Human Oocytes that Were Collected From Resected Ovarian Tissue and Matured In Vitro. Stem Cells and Development, 2009, 18, 941-946.	2.1	2
47	Lin28 promotes transformation and is associated with advanced human malignancies. Nature Genetics, 2009, 41, 843-848.	21.4	742
48	Constitutive Activation of Beta-Catenin in Uterine Stroma and Smooth Muscle Leads to the Development of Mesenchymal Tumors in Mice1. Biology of Reproduction, 2009, 81, 545-552.	2.7	129
49	Progressive Spermatogonial Stem Cell Loss in Mice with Constitutively Activated Beta-Catenin in Postpubertal Sertoli Cells is Associated with Persistent Expression of GDNF and MIS.. Biology of Reproduction, 2009, 81, 74-74.	2.7	0
50	Normal ovarian surface epithelial label-retaining cells exhibit stem/progenitor cell characteristics. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 12469-12473.	7.1	127
51	Evidence of a Role for Androgens in Embryonic Stem Cell Function and Differentiation. Endocrinology, 2008, 149, 3-4.	2.8	7
52	c-Jun N-terminal Kinase Inhibitor II (SP600125) Activates Muì`llerian Inhibiting Substance Type II Receptor-Mediated Signal Transduction. Endocrinology, 2008, 149, 108-115.	2.8	24
53	Utility of serum antimÃ¼llerian hormone/MÃ¼llerian-Inhibiting Substance for predicting ovarian reserve in older women. Menopause, 2008, 15, 824-826.	2.0	1
54	Activin receptor-like kinase-2 inhibits activin signaling by blocking the binding of activin to its type II receptor. Journal of Endocrinology, 2007, 195, 95-103.	2.6	23

#	Article	IF	Citations
55	Adult Mouse Myometrial Label-Retaining Cells Divide in Response to Gonadotropin Stimulation. Stem Cells, 2007, 25, 1317-1325.	3.2	87
56	Mulˆllerian inhibiting substance regulates its receptor/SMAD signaling and causes mesenchymal transition of the coelomic epithelial cells early in Mulˆllerian duct regression. Development (Cambridge), 2006, 133, 2359-2369.	2.5	69
57	Conditional deletion of Î²-catenin in the mesenchyme of the developing mouse uterus results in a switch to adipogenesis in the myometrium. Developmental Biology, 2005, 288, 276-283.	2.0	180
58	Feedback Inhibition of Steroidogenic Acute Regulatory Protein Expressionin Vitroandin Vivoby Androgens. Endocrinology, 2004, 145, 1269-1275.	2.8	59
59	Genomic structure and expression analysis of the mouse testis-specific ribbon protein (Trib) gene. Gene, 2004, 343, 221-227.	2.2	3
60	Steroidogenic activities in MA-10 Leydig cells are differentially altered by cAMP and MÃ¼llerian inhibiting substance. Journal of Steroid Biochemistry and Molecular Biology, 2004, 92, 199-208.	2.5	19
61	Enhanced purification and production of MÃ¼llerian inhibiting substance for therapeutic applications. Molecular and Cellular Endocrinology, 2003, 211, 37-42.	3.2	29
62	Inhibition of steroidogenesis in Leydig cells by MÃ¼llerian-inhibiting substance. Molecular and Cellular Endocrinology, 2003, 211, 99-104.	3.2	36
63	Regulation of gonadotropin gene expression by MÃ¼llerian inhibiting substance. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 9348-9353.	7.1	60
64	MÃ¼llerian Inhibiting Substance Blocks the Protein Kinase A-Induced Expression of Cytochrome P450 17Î±-Hydroxylase/C17â€“20Lyase mRNA in a Mouse Leydig Cell Line Independent of cAMP Responsive Element Binding Protein Phosphorylation. Endocrinology, 2002, 143, 3351-3360.	2.8	50
65	New approaches for high-yield purification of MÃ¼llerian inhibiting substance improve its bioactivity. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2002, 766, 89-98.	2.3	36
66	Perspective: Reproductive Tract Developmentâ€"New Discoveries and Future Directions. Endocrinology, 2001, 142, 2167-2172.	2.8	32
67	Mulˆllerian Inhibiting Substance: An Instructive Developmental Hormone with Diagnostic and Possible Therapeutic Applications. Endocrine Reviews, 2001, 22, 657-674.	20.1	255
68	Mullerian Inhibiting Substance lowers testosterone in luteinizing hormone-stimulated rodents. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 3393-3397.	7.1	53
69	Perspective: Reproductive Tract Development--New Discoveries and Future Directions. Endocrinology, 2001, 142, 2167-2172.	2.8	9
70	Mulˆllerian-Inhibiting Substance Regulates Androgen Synthesis at the Transcriptional Level1. Endocrinology, 1999, 140, 4732-4738.	2.8	91
71	Transcriptional regulation of the rat MÃ¼llerian inhibiting substance type II receptor in rodent Leydig cells. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 13831-13838.	7.1	43
72	Mullerian-Inhibiting Substance Regulates Androgen Synthesis at the Transcriptional Level. Endocrinology, 1999, 140, 4732-4738.	2.8	30

#	Article	IF	Citations
73	MÃ¼llerian Inhibiting Substance Inhibits Branching Morphogenesis and Induces Apoptosis in Fetal Rat Lung1. Endocrinology, 1997, 138, 790-796.	2.8	47
74	Mullerian Inhibiting Substance Inhibits Branching Morphogenesis and Induces Apoptosis in Fetal Rat Lung. Endocrinology, 1997, 138, 790-796.	2.8	15
75	MULLERIAN INHIBITING SUBSTANCE IN BRANCHING MORPHOGENESIS OF FETAL LUNG.â€¢ 1952. Pediatric Research, 1996, 39, 328-328.	2.3	0
76	A STAT Factor Mediates the Sexually Dimorphic Regulation of Hepatic Cytochrome P450 3A10/Lithocholic Acid 6Î²-Hydroxylase Gene Expression by Growth Hormone. Molecular and Cellular Biology, 1995, 15, 4672-4682.	2.3	63